Limited SUMOylation inhibitor administration enhances eradication of Burkitt’s lymphoma with CD19 CAR-T therapy (IMAGE)

Kanazawa University

Limited SUMOylation inhibitor administration enhances eradication of Burkitt’s lymphoma with CD19 CAR-T therapy

Caption

Treatment schedule in an immunocompetent mouse model bearing a high burden of Burkitt’s lymphoma. While conventional CAR-T therapy alone resulted in no cures, adding five doses of a SUMOylation inhibitor led to long-term survival in 80% of the mice.

Credit

Kanazawa University

Usage Restrictions

Credit must be given to the creator.

License

CC BY

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.